Literature DB >> 17716723

Severe serum sickness-like syndrome after omalizumab therapy for asthma.

Charles Pilette, Nathalie Coppens, Frédéric A Houssiau, Daniel O Rodenstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17716723     DOI： 10.1016/j.jaci.2007.06.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  5 in total

Review 1.  Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.

Authors:  Rafael Bonamichi-Santos; Mariana Castells
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 2.  Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.

Authors:  Jamie L Waldron; Stephen A Schworer; Mildred Kwan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-28       Impact factor: 8.667

3.  Immunologic evaluation of drug allergy.

Authors:  Enrique Gómez; Maria Jose Torres; Cristobalina Mayorga; Miguel Blanca
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-30       Impact factor: 5.764

4.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

Review 5.  Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.

Authors:  G J Molderings; F L Dumoulin; J Homann; B Sido; J Textor; M Mücke; G J Qagish; R Barion; M Raithel; D Klingmüller; V S Schäfer; H J Hertfelder; D Berdel; G Tridente; L B Weinstock; L B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-05-06       Impact factor: 3.000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.